All articles by Miranda Mclaren
Miranda Mclaren
Rare Disease Day: Why raising awareness is essential for a fairer future
This Rare Disease Day, we look at the role increased awareness and improved pharmaceutical market conditions can play in closing the treatment inequality gap for rare disease patients.
How early planning leads to successful market access and drug launch in Europe
It is never too early in the product lifecycle to start developing a market access and pricing and reimbursement strategy, particularly when navigating the complex landscape of the European region.
The EU joint HTA procedure: a gate or barrier for access?
The joint health technology assessment (HTA) procedure was a hot topic at the World Orphan Drug Congress – Europe (WODC-EU) in Barcelona last month, and opinions were mixed.
Low-code/no-code platforms and SaaS: the next evolution in clinical trial technology
The adoption of sophisticated software practices has the potential to spur some powerful innovations in clinical trials, making trials quicker and easier to set up while ensuring a smooth digital experience for patients.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
How to cut drug supply costs with seamless forecasting and IRT systems
Cut drug wastage, reduce risk, and optimise supply with advanced, integrated technologies designed to deliver increased visibility, flexibility and accuracy.
Medical affairs in a digital-first world: Benefits and challenges
From telehealth to decentralised trials, the entire healthcare industry has realised the true value of digitalisation in recent years. Medical affairs teams are no exception. Here, we discuss the benefits and challenges of engaging medical professionals on digital channels.
Tech innovations that curb complexity, setting clinical trials up for success
With trial complexity on the rise, studies leverage innovative technologies to help drive successful outcomes.
eConsent adoption: Top three stumbling blocks holding sponsors back
No clinical study can take place without informed consent. But with studies becoming increasingly complex and often remote, it’s the right time to take that step forward to reimagine how the consent process is managed.